Scisparc Ownership
| SPRC Stock | USD 7.26 0.43 5.59% |
Shares in Circulation | First Issued 2012-06-30 | Previous Quarter 10.8 M | Current Value 2 M | Avarage Shares Outstanding 9.4 M | Quarterly Volatility 25.3 M |
Scisparc Stock Ownership Analysis
The company has price-to-book ratio of 0.5. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Scisparc recorded a loss per share of 22.65. The entity had not issued any dividends in recent years. The firm had 1:21 split on the 3rd of July 2025. SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Scisparc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Scisparc contact Oz CPA at 972 7 334 47180 or learn more at https://scisparc.com.Besides selling stocks to institutional investors, Scisparc also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Scisparc's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Scisparc's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Scisparc Quarterly Liabilities And Stockholders Equity |
|
Scisparc Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Scisparc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Scisparc backward and forwards among themselves. Scisparc's institutional investor refers to the entity that pools money to purchase Scisparc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Securities, Llc | 2025-03-31 | 67.4 K | Sbi Securities Co Ltd | 2025-03-31 | 285 | Bank Of America Corp | 2025-03-31 | 42.0 | Rhumbline Advisers | 2025-03-31 | 16.0 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 5.0 | Susquehanna International Group, Llp | 2025-03-31 | 0.0 | Jpmorgan Chase & Co | 2025-03-31 | 0.0 | Virtu Financial Llc | 2024-12-31 | 0.0 | Ubs Group Ag | 2025-03-31 | 0.0 |
Scisparc Outstanding Bonds
Scisparc issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Scisparc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Scisparc bonds can be classified according to their maturity, which is the date when Scisparc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Scisparc Corporate Filings
6K | 22nd of July 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 21st of July 2025 Other Reports | ViewVerify | |
| 8th of July 2025 Other Reports | ViewVerify | |
| 18th of June 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Scisparc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scisparc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scisparc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scisparc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scisparc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Scisparc Stock refer to our How to Trade Scisparc Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scisparc. If investors know Scisparc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scisparc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (22.65) | Revenue Per Share | Quarterly Revenue Growth (0.49) | Return On Assets | Return On Equity |
The market value of Scisparc is measured differently than its book value, which is the value of Scisparc that is recorded on the company's balance sheet. Investors also form their own opinion of Scisparc's value that differs from its market value or its book value, called intrinsic value, which is Scisparc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scisparc's market value can be influenced by many factors that don't directly affect Scisparc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scisparc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scisparc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scisparc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.